+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Axial Spondyloarthritis Drug"

From
Axial Spondyloarthritis (AxSpA) Market Report 2025 - Product Thumbnail Image

Axial Spondyloarthritis (AxSpA) Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
From
Axial Spondyloarthritis - Pipeline Insight, 2024 - Product Thumbnail Image

Axial Spondyloarthritis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
From
From
US Axial Spondyloarthritis Market outlook to 2028 - Product Thumbnail Image

US Axial Spondyloarthritis Market outlook to 2028

  • Report
  • October 2023
  • 85 Pages
  • United States
From
Axial Spondyloarthritis (axSpA) - Epidemiology Forecast - 2032 - Product Thumbnail Image

Axial Spondyloarthritis (axSpA) - Epidemiology Forecast - 2032

  • Drug Pipelines
  • February 2022
  • 114 Pages
  • Global
From
From
From
From
From
From
  • 18 Results (Page 1 of 1)
Loading Indicator

Axial Spondyloarthritis (axSpA) is a type of inflammatory arthritis that affects the spine and sacroiliac joints. It is a chronic, progressive condition that can cause pain, stiffness, and swelling in the affected areas. Immune Disorders Drugs are used to treat axSpA, as they help to reduce inflammation and pain. These drugs can be taken orally, injected, or infused, depending on the severity of the condition. Commonly used drugs include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), biologic agents, and corticosteroids. The Axial Spondyloarthritis Drug market is a rapidly growing segment of the Immune Disorders Drugs market. It is driven by the increasing prevalence of axSpA, as well as the development of new drugs and treatments. Companies in the market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB. Show Less Read more